Blog featured

April 20, 2022 Nexelis

Nexelis, a Q² Solutions Company, Wins Best Central/Speciality Laboratory Award at the 2022 Vaccine Industry Excellence Awards

We are celebrating this week as Nexelis has been recognized at the Vaccine Industry Excellence (ViE) awards, in Washington DC.

Read More

Blog

March 25, 2022 Nexelis

Interlaboratory Comparative Study of HAI Assays

Influenza vaccine development is a unique paradox. A seasonal influenza formulation is constructed from four strains selected by organizations such as WHO and CDC. The strain selection is then...

Blog

December 15, 2021 Nexelis

Taking a biomarker-led approach to R&D

Leveraging biomarkers in the clinical field isn’t a new concept. In fact, their value has been well documented in treatments for patients and in the development of new precision medicines. However,...

Blog

November 17, 2021 Nexelis

Industry collaboration is at an all-time high – but how do we take this beyond the COVID-19 pandemic?

The COVID-19 pandemic has seen exceptional collaboration amongst key industry partners including pharmaceutical companies, manufacturers, government and academia, and one major result of this...

Blog

August 16, 2021 Nexelis

Immuno-Oncology: Functional Assays for Immune Checkpoint Inhibitors as Emerging Therapeutics

In this recent webinar, immuno-oncology experts Sofie Pattijn, chief technology officer and co-founder of ImmunXperts, a Nexelis company, and Thibaut Janss, lead scientist, ImmunXperts, answer the...

Blog

June 28, 2021 Nexelis

Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2

In this recent webinar, Bassam Hallis, Ph.D., Head of Preclinical Development for Public Health England, and Luc Gagnon, VP of Vaccine Sciences for Nexelis, discuss pandemic preparedness and response...

Blog

June 28, 2021 Nexelis

Where the Science Leads Us: Bispecific Antibodies

There’s a reason that Nexelis is the leading specialty lab for what’s next in therapeutic testing and assay development. Our corporate DNA is built from scientific rigor, premium facilities, and the...

Blog

May 30, 2021 Nexelis

Where the Science Leads Us: SARS-CoV-2

By March 2020, when the World Health Organization declared SARS-CoV-2 a pandemic, every major multinational pharmaceutical company, innovative biotechnology company, governmental, and nongovernmental...